Compounds > 9-methoxy-n(2)-methylellipticinium iodide
Page last updated: 2024-12-10

9-methoxy-n(2)-methylellipticinium iodide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3086380
CHEMBL ID68096
MeSH IDM0326840

Synonyms (16)

Synonym
9-methoxy-2,5,11-trimethyl-6h-pyrido(4,3-b)carbazolium iodide
9-methoxy-2-methylellipticinium iodide
methyl 2,5,11-trimethyl-6h-2.lambda.~5~-pyrido[4,3-b]carbazol-9-yl ether
{6h-pyrido[4,3-b]carbazolium,} 9-methoxy-2,5,11-trimethyl-,iodide
9-methoxy-2,5,11-trimethyl-6h-2.lambda.~5~-pyrido[4,3-b]carbazole
9-methoxy-2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium iodide
93841-50-0
nsc155693
nsc 155693
nsc-155693
6h-pyrido[4, 9-methoxy-2,5,11-trimethyl-,iodide
mls002702527 ,
CHEMBL68096
einecs 299-020-2
9-methoxy-2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium;iodide
9-methoxy-2,5,11-trimethyl-6h-pyrido[4,3-b]carbazolium iodide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency14.12540.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency5.62340.01846.806014.1254AID624417
WRNHomo sapiens (human)Potency22.38720.168331.2583100.0000AID651768
TDP1 proteinHomo sapiens (human)Potency0.25930.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720579; AID720580
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
flap endonuclease 1Homo sapiens (human)Potency1.79230.133725.412989.1251AID588795; AID720498
DNA polymerase eta isoform 1Homo sapiens (human)Potency5.32520.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency7.79140.050127.073689.1251AID588590; AID720496
DNA polymerase kappa isoform 1Homo sapiens (human)Potency6.27860.031622.3146100.0000AID588579; AID720501
VprHuman immunodeficiency virus 1Potency4.46681.584919.626463.0957AID651644
Guanine nucleotide-binding protein GHomo sapiens (human)Potency25.11891.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SUMO-1Homo sapiens (human)IC50 (µMol)38.07500.64707.494715.9000AID624382; AID624383
integrase, partialHuman immunodeficiency virus 1IC50 (µMol)21.99300.07953.52039.9390AID1053171; AID1053172
lens epithelium-derived growth factor p75Homo sapiens (human)IC50 (µMol)21.99300.07953.52039.9390AID1053171; AID1053172
rac GTPase-activating protein 1 isoform aHomo sapiens (human)IC50 (µMol)24.74007.390057.8904301.2400AID624330
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LANAHuman gammaherpesvirus 8AC5033.86350.042032.4569312.0010AID504726; AID504727
protein AF-9 isoform aHomo sapiens (human)AC503.07000.08008.380217.9800AID720495
DNA repair protein RAD52 homolog isoform aHomo sapiens (human)AC500.15000.150012.066235.2100AID652116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID90125Concentration yielding an amount of cellular protein at the end of the incubation that is the same as at the beginning of the incubation in brain tumor sub panel1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID614179Effect on membrane integrity in Staphylococcus aureus SH1000 at four times MIC after 10 mins by BacLight assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase.
AID614176Antimicrobial activity against AcrAB-deficient Escherichia coli SM1411 after 18 hrs by broth microdilution method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase.
AID90126Concentration yielding an amount of cellular protein at the end of the incubation that is the same as at the beginning of the incubation in full panel1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID235001TGI correlation coefficient value of the compound1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID231710Ratio between brain tumor full panel [A] and sub panel [B]1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID234620Selective rating against brain tumor cell line panel; i selective (**) if (A/B)> 6 and TGI-Corr > 0.81994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID614180Inhibition of Escherichia coli DdlB assessed as residual activity of the enzyme assessed as orthophosphate formation at 500 uM after 20 mins by malachite green reagent method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase.
AID614175Antimicrobial activity against Escherichia coli 1411 after 18 hrs by broth microdilution method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase.
AID614174Inhibition of Escherichia coli DdlB assessed as residual activity of the enzyme assessed as orthophosphate formation after 20 mins by malachite green reagent method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase.
AID614177Antimicrobial activity against Staphylococcus aureus SH1000 after 18 hrs by broth microdilution method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nsc-526417
[no description available]		2.0710
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		1.9810indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.0710dihydroxyanthraquinoneanalgesic;
antineoplastic agent
purpurin
purpurin: from Rubiaceae plants; structure in first source. purpurin : A trihydroxyanthraquinone derived from anthracene by substitution with oxo groups at C-9 and C-10 and with hydroxy groups at C-1, C-2 and C-4.		2.0710trihydroxyanthraquinonebiological pigment;
histological dye;
plant metabolite
acriflavine chloride
3,6-diamino-10-methylacridinium chloride : The 10-methochloride salt of 3,6-diaminoacridine. Note that a mixture of this compound with 3,6-diaminoacridine (proflavine) is known as acriflavine or neutral acriflavine.		2.0710organic chloride saltantibacterial agent;
antiseptic drug;
carcinogenic agent;
histological dye;
intercalator
pyronine
Pyronine: Xanthene dye used as a bacterial and biological stain. Synonyms: Pyronin; Pyronine G; Pyronine Y. Use also for Pyronine B. which is diethyl-rather than dimethylamino-.. pyronin Y : An organic chloride salt having 6-(dimethylamino)-N,N-dimethyl-3H-xanthen-3-iminium as the cation. Used with methyl green to selectively demonstrate RNA (red) in contrast to DNA (green) with the Unna-Pappenheim method.		2.0710iminium salt;
organic chloride salt		histological dye
1-amino-4-hydroxyanthraquinone
[no description available]		2.0710
5-amino-2-naphthalenesulfonate
[no description available]		2.0710aminonaphthalenesulfonic acid
rhein
[no description available]		2.0710dihydroxyanthraquinone
c 137
C 137: RN given refers to parent cpd		2.0710
ethidium bromide
[no description available]		2.0710organic bromide saltgeroprotector;
intercalator;
trypanocidal drug
rafoxanide
Rafoxanide: Veterinary anthelmintic for grazing animals; used to treat fluke, hookworm and other infestations.		2.0710
(7S,9S)-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
[no description available]		2.0710anthracycline
elliptinium acetate
[no description available]		1.9810
daunorubicin hydrochloride
[no description available]		2.0710anthracycline
dimidium bromide
[no description available]		2.0710
datelliptium chloride
detalliptinium: structure given in first source		1.9810
9-methoxyellipticine
9-methoxyellipticine: RN given refers to parent cpd		2.4220
2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid
2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid: structure given in first source		2.0710
9-hydroxyellipticine
9-hydroxyellipticine: RN given refers to parent cpd. 9-hydroxyellipticine : A organic heterotetracyclic compound that is ellipticine in which the hydrogen at position 9 has been replaced by a hydroxy group.		2.4220organic heterotetracyclic compound;
organonitrogen heterocyclic compound		antineoplastic agent
olivacine
olivacine: alkaloid with antitumor & antileukemic activity isolated from Aspidosperma olivaceum; structure; RN given refers to parent cpd		1.9810
2-(4-hydroxyphenyl)-5,6,7,8-tetrahydroxy-4H-1-benzopyran-4-one
2-(4-hydroxyphenyl)-5,6,7,8-tetrahydroxy-4H-1-benzopyran-4-one : A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 6, 7, 8, and 4' respectively.		2.0710pentahydroxyflavone
4-chloro-3-(2,4-dihydroxyphenylazo)-2-hydroxybenzene-1-sulfonic acid
[no description available]		2.0710
phacidin
phacidin: fungal growth inhibitor from Potebniamyces balsamicola var. boycei; also active against bacteria		2.0710
3'-deamino-3'-hydroxydaunorubicin
3'-deamino-3'-hydroxydaunorubicin: structure given in first source		2.0710
nsc 36398
NSC 36398: structure in first source		2.0710
nsc 74859
NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.		2.0710amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
nsc-260594
NSC-260594: structure in first source		2.0710
hematoxylin
[no description available]		2.0710haematoxylin
nsc668394
[no description available]		2.0710
n,n-dimethyldaunorubicin
[no description available]		2.0710
jp-1302
[no description available]		2.0710
calmidazolium
calmidazolium chloride : The organic choride salt of calmidazolium.		2.0710organic chloride saltapoptosis inducer;
calmodulin antagonist
2-[[5-[[2-(3-chloroanilino)-4-thiazolyl]methyl]-4-(3-methoxypropyl)-1,2,4-triazol-3-yl]thio]acetic acid methyl ester
[no description available]		2.0710aryl sulfide
4-[(4-carboxy-2,6-dimethoxyphenoxy)methyl]-5-methyl-2-furancarboxylic acid
[no description available]		2.0710trihydroxybenzoic acid
umi-77
UMI-77: an Mcl-1 inhibitor; structure in first source		2.0710
N-cyclohexyl-2-[(8-methoxy-6-oxo-3-benzo[c][1]benzopyranyl)oxy]acetamide
[no description available]		2.0710coumarins
3-(5,8-dinitro-1,3-dioxo-2-benzo[de]isoquinolinyl)benzoic acid
[no description available]		2.0710nitronaphthalene
N-[3-(benzenesulfonyl)-1-cyclohexyl-2-pyrrolo[3,2-b]quinoxalinyl]benzenesulfonamide
[no description available]		2.0710quinoxaline derivative
3-(2-furanyl)-N-[3-(2-furanyl)-4-methylpentyl]-4-phenylbutanamide
[no description available]		2.0710fatty amide
gw 7647
GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.		2.0710aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
N-[(4-methylphenyl)methyl]-4-(1-pyrrolyl)benzamide
[no description available]		2.0710benzamides
gamma-linolenic acid
gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed). gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.		2.0710linolenic acid;
omega-6 fatty acid		human metabolite;
mouse metabolite;
plant metabolite
alpha-linolenic acid
linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.		2.0710linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
diosmin
[no description available]		2.0710dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
myricetin
[no description available]		2.07107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
4-[(3aR,4S,9bS)-8-[(4-methoxyphenyl)sulfamoyl]-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl]benzoic acid
[no description available]		2.0710quinolines
ag 538
AG 538: an IGF-1 receptor kinase inhibitor; structure in first source		2.0710
Diosmetin rutinoside
[no description available]		2.0710flavonoids;
glycoside
cefixime
[no description available]		2.0710cephalosporinantibacterial drug;
drug allergen
10H-phenanthro[9,10-g]pteridine-11,13-dione
[no description available]		2.0710flavin
thunberginol b
thunberginol B: isolated from Hydrangeae dulcis folium; structure given in first source		2.0710
3-(dimethylamino)benzoic acid (7-hydroxy-2-oxo-1-benzopyran-4-yl)methyl ester
[no description available]		2.0710hydroxycoumarin
carmine
carminic acid : A tetrahydroxyanthraquinone that is that is 1,3,4,6-tetrahydroxy-9,10-anthraquinone substituted by a methyl group at position 8, a carboxy group at position 7 and a 1,5-anhydro-D-glucitol moiety at position 2 via a C-glycosidic linkage. It is a natural dye isolated from several insects such as Dactylopius coccus.		2.0710C-glycosyl compound;
monocarboxylic acid;
tetrahydroxyanthraquinone		animal metabolite;
histological dye
cefotaxime sodium
[no description available]		2.0710organic sodium salt
N-[4-(diethylamino)-2-methylphenyl]-2-[(2-nitro-3-thiophenyl)thio]acetamide
[no description available]		2.0710anilide
3,6-diamino-10-methylacridinium chloride hydrochloride
3,6-diamino-10-methylacridinium chloride.HCl : A hydrochloride resulting from the reaction of equimolar amounts of 3,6-diamino-10-methylacridinium chloride and hydrogen chloride.		2.0710hydrochlorideantibacterial agent;
antiseptic drug;
carcinogenic agent;
intercalator
quercetin
[no description available]		2.0710
montelukast sodium
[no description available]		2.0710organic sodium salt
acid blue 129
[no description available]		2.0710
N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-5-bromo-2-furancarboxamide
[no description available]		2.0710acetamides;
anilide
navitoclax
[no description available]		2.0710aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
6-(3-cyclopentyloxy-4-methoxyphenyl)-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
[no description available]		2.0710triazoles
3-(2-chlorophenyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
[no description available]		2.0710triazoles
6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
[no description available]		2.0710triazoles
6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
[no description available]		2.0710triazoles
3-(2-chlorophenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
[no description available]		2.0710triazoles
6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-3-[2-(trifluoromethyl)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
[no description available]		2.0710triazoles
methacycline monohydrochloride
[no description available]		2.0710
galloflavin
galloflavin: structure in first source		2.0710
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms, Brain
[description not available]		01.9810
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9810
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510